ArticleJugan geon-gang gwa jilbyeong2023
[Treatment Outcomes among Drug-susceptible Patients with Tuberculosis in the Republic of Korea, 2019-2020].
Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Vulnerability Assessment and Enhanced Community-based Care and Management of Patients With Tuberculosis in Korea: A Crossover Design.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025Article
- Impact of Mass Screening Using Chest X-Ray on Mortality Reduction and Treatment Adherence Among Pulmonary Tuberculosis Patients.Journal of Korean medical science · 2024Article
- Risk Factors for Unfavorable Outcomes of Tuberculosis in Korea: Implications for Patient-Centered Care in Tuberculosis Treatment.Journal of Korean medical science · 2024Article
- [The Korean National Public-Private Mix Tuberculosis Control Project: Analysis of the Indicators for Tuberculosis Management in 2021].Jugan geon-gang gwa jilbyeong · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of patients with tuberculosis (TB) in the Republic of Korea (ROK) has decreased by 7.4% on average each year over the past decade since reaching its peak in 2011 (39,557 cases) and declined to more than 50% in 2021. To continue reducing the number of patients with TB, an improvement in the TB treatment success rate (TSR) is required. The World Health Organization considers the "TB TSR" as a significant indicator for TB control, with a target reaching at least "90%." In ROK, the TSR and mortality rate among all patients with TB was 80.1% and 14.8% in 2020 and decreased by 1.8% and increased by 1.7%, respectively, compared with the rates in 2019. The TB TSR among aged 65 years and older was the lowest at 70.8% (extra-pulmonary TB, 82.6%; smear-negative pulmonary TB, 81.6%; and smear-positive pulmonary TB, 74.7%). The TSR was 6.1% higher in new patients (81.3%) than that in previously treated patients (75.2%), and the treatment interruption rate was two times higher in previously treated patients (3.6%) than in new patients (1.8%). Various efforts are necessary to improve the TSR not only by investigating the cause of death but also developing relevant policies and projects to support vulnerable patients that target groups with have a relatively low TSR, including smear-positive and previously treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.